Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial

Publication date: 25–31 January 2020Source: The Lancet, Volume 395, Issue 10220Author(s): Andrew Lotery, Sobha Sivaprasad, Abby O'Connell, Rosie A Harris, Lucy Culliford, Lucy Ellis, Angela Cree, Savita Madhusudhan, Francine Behar-Cohen, Usha Chakravarthy, Tunde Peto, Chris A Rogers, Barnaby C Reeves, Samir Bellani, Helen Griffiths, Suresh Thulasidharan, Catrin Watkins, Rebecca Kaye, Deepthy Menon, Qin NevilleSummaryBackgroundIn chronic central serous chorioretinopathy (CSCR), fluid accumulates in the subretinal space. CSCR is a common visually disabling condition that develops in individuals up to 60 years of age, and there is no definitive treatment. Previous research suggests the mineralocorticoid receptor antagonist, eplerenone, is effective for treating CSCR; however, this drug is not licensed for the treatment of patients with CSCR. We aimed to evaluate whether eplerenone was superior to placebo in terms of improving visual acuity in patients with chronic CSCR.MethodsThis randomised, double-blind, parallel-group, multicentre placebo-controlled trial was done at 22 hospitals in the UK. Participants were eligible if they were aged 18–60 years and had had treatment-naive CSCR for 4 months or more. Patients were randomly assigned (1:1) to either the eplerenone or the placebo group by a trial statistician through a password-protected system online. Allocation was stratified by best-corrected visual acuity (BCVA) and hospital. Patients were given either oral eplerenone (2...
Source: The Lancet - Category: General Medicine Source Type: research